Results Healthcare is delighted to have been the exclusive financial advisor to Arxspan, a provider of cloud-based lab informatics solutions for the pharmaceutical, biotechnology, and chemical industries, on its sale to Bruker Corporation (NasdaqGS: BRKR), a manufacturer of scientific instruments and analytical solutions.
Founded in 2011, Arxspan developed into one of the leading lab informatics companies with an established customer base in the United States, and a growing market share in Europe and Asia. Arxspan offer a product suite that includes an Electronic Lab Notebook (ELN), Workflow, Inventory System, Chemical and Biological Registration, and Assay Management. It has become a prominent player uniquely positioned to take advantage of the migration to web-based, real-time, distributed collaboration solutions in the $2.5 billion global lab informatics market. With a comprehensive blend of lab informatics products delivered through a strong SaaS platform, Arxspan saw years of growing momentum as a single solution designed to support scientific research and collaboration.
Having experienced strong growth since inception, including market penetration in China, Japan, the UK, and Germany, the opportunity presented itself to seek a partner to improve existing sample management, data analytics, and SDMS/LIMS capabilities. With scientific instrumentation and R&D hardware companies expanding into digital health via acquisition to become more user-centric, Arxspan was perfectly situated to take advantage of the growing interest in its capabilities.
Results Healthcare was chosen as the financial advisor to help Arxspan with its strategic growth initiatives given our experience in similar lab informatics transactions, and understanding of the capabilities strategic and financial buyers are targeting.
Following a comprehensive sweep of potential acquirers from a multitude of verticals including lab equipment, health tech, CROs, technology, and PE, Results Healthcare identified a select number of suitable parties. Following the submission of several compelling bids, we assisted Arxspan in its decision to go with Bruker because of the latter’s demonstrated commitment to investing in the growth of its burgeoning pharmaceutical, biotechnology, and chemical software business.
Peter Rosati, CEO at Arxspan:
“The team at Results Healthcare has many strong relationships with both the strategic and financial buyers in the Health Tech/Informatics sector. The advice we received was insightful throughout the entire process. We highly recommend them to anyone in our sector considering a strategic transaction as the next step for their business”.